Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY: OGN )

15.48 -0.65 (-4.03%)
Official Closing Price Updated: 7:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,909,113
Open 16.04
Bid (Size) 15.48 (3)
Ask (Size) 15.55 (1)
Prev. Close 16.13
Today's Range 15.38 - 16.12
52wk Range 13.87 - 23.10
Shares Outstanding N/A
Dividend Yield 7.24%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
High-Yield Healthcare: 3 Stocks With Strong Dividends
This article covers three healthcare stocks that offer dividend yields of at least 7% and dives deeper into the fundamentals to determine if they're good buys. 
Via MarketBeat

Performance

YTD
+3.48%
+3.48%
1 Month
-4.80%
-4.80%
3 Month
-3.13%
-3.13%
6 Month
-31.11%
-31.11%
1 Year
-14.19%
-14.19%

More News

Read More
Organon (OGN) Shares Skyrocket, What You Need To Know
Via StockStory
Topics Initial Public Offering
Exposures Securities Market
Organon (NYSE:OGN) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Via StockStory
Earnings Scheduled For February 13, 2025
Via Benzinga
Looking Into Organon's Recent Short Interest
Via Benzinga
P/E Ratio Insights for Organon
Via Benzinga
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
From Organon & Co.
Via Business Wire
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Via StockStory
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
From Organon & Co.
Via Business Wire
Want $2,000 in Annual Dividends? Invest $11,000 in Each of These 3 Stocks.
Via The Motley Fool
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
From Organon & Co.
Via Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2024
From Organon & Co.
Via Business Wire
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
From Organon & Co.
Via Business Wire
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Organon & Co.
Via Business Wire
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 Stocks
Via The Motley Fool
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
Via Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
From Organon & Co.
Via Business Wire
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
Via Benzinga
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
From Organon & Co.
Via Business Wire
Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.